Litigation Details for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (D. Del. 2021)

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (D. Del. 2021)

Docket	1:21-cv-01594	Date Filed	2021-11-10
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Both	Referred To
Patents	10,272,062; 10,736,866; 10,952,986; 10,973,795; 6,228,398; 6,309,663; 6,419,960; 6,514,531; 6,913,768; 7,268,156; 8,101,209; 8,731,963
Link to Docket	External link to docket

Details for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-11-10				External link to document
2021-11-09	142	Decision C.A. No. 22-2159 (D.D.C.)	Distribution System and Method, U.S. Patent No. 8,731,963 (“the ‘963 Patent”). Jazz’s oxybate drugs are distributed…2) a “Patent Statement,” which represents that no existing patents listed in the FDA’s patent database…existing patent or why the existing patent is invalid. Id. § 355(b)(2)(A)(i)–(iv). 3 A Patent Certification…submitting a Patent Statement. On May 24, 2022, the FDA rejected Avadel’s Patent Statement. It…claimed by an existing method-of-use patent held by Jazz (the “Patent Decision”). On June 6, 2022, Avadel	External link to document
2021-11-10	146	Memorandum Opinion	alleges infringement of U.S. Patent Nos. 8,731,963 ("the '963 patent"), 10,758,488 ("…quot;the ' 488 patent"), 10,813 ,885 ("the ' 885 patent"), 10,959,956 ("…quot;the ' 956 patent"), 10,966,931 ("the ' 931 patent"), 11 ,077,079 ("the…the ' 079 patent"), and 11,147,782 ("the '782 patent"). 1 Before the Court is…quot; It is a bedrock principle of patent law that the claims of a patent define the invention to which	External link to document

Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: August 4, 2026

Jazz Pharmaceuticals’ patent case against Avadel CNS Pharmaceuticals concerned LUMRYZ, Avadel’s once-nightly extended-release sodium oxybate product for narcolepsy. The litigation centered on two Jazz patents listed for Xyrem, U.S. Patent Nos. 8,731,963 and 10,758,488. The district court held the asserted patent claims invalid for lack of written description, eliminating Jazz’s principal patent-based barrier to LUMRYZ commercialization. The Federal Circuit later affirmed the invalidity ruling. Avadel launched LUMRYZ in 2023 after FDA approval.

What was Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals?

Jazz Pharmaceuticals, Inc. sued Avadel CNS Pharmaceuticals, LLC in the U.S. District Court for the District of Delaware on November 5, 2021. The case was docketed as Civil Action No. 1:21-cv-01594.

Jazz alleged that Avadel’s proposed LUMRYZ product would infringe patents covering sodium oxybate formulations and dosing methods associated with Xyrem. Avadel filed an abbreviated new drug application or other generic-style regulatory challenge, prompting Jazz to assert Orange Book-listed patents under the Hatch-Waxman framework.

The dispute involved an important product distinction:

Product	Company	Active ingredient	Dosing profile	Regulatory status
Xyrem	Jazz Pharmaceuticals	Sodium oxybate	Two nighttime doses	FDA-approved
Xywav	Jazz Pharmaceuticals	Calcium, magnesium, potassium and sodium oxybates	Two nighttime doses	FDA-approved
LUMRYZ	Avadel Pharmaceuticals	Sodium oxybate	Once-nightly extended release	FDA-approved May 1, 2023

LUMRYZ uses an extended-release formulation designed to provide sodium oxybate during the night from a single bedtime dose. Jazz’s patent strategy sought to extend control over sodium oxybate products beyond the core Xyrem formulation patents.

What patents did Jazz assert against Avadel?

Jazz asserted U.S. Patent Nos. 8,731,963 and 10,758,488. Both patents were associated with sodium oxybate treatment and formulation technology and were listed in the FDA’s Orange Book for Xyrem.

Patent	Core subject matter	Asserted against Avadel	Court outcome
U.S. 8,731,963	Sodium oxybate formulation and administration technology	Yes	Claims held invalid
U.S. 10,758,488	Related sodium oxybate formulation and dosing technology	Yes	Claims held invalid

The asserted patents were continuation or related-family patents built on Jazz’s broader sodium oxybate intellectual-property platform. Their strategic value extended beyond Xyrem because they were directed at formulation and administration concepts that could potentially reach competing sodium oxybate products.

Jazz’s claims focused on the technical and therapeutic characteristics of sodium oxybate treatment, including formulation performance, dosing conditions and controlled delivery. The infringement dispute therefore depended on whether LUMRYZ’s once-nightly extended-release design fell within the scope of the asserted claims.

What was the litigation timeline in Jazz v. Avadel?

Date	Event
November 2021	Jazz filed the patent infringement action in the District of Delaware.
2022	The parties litigated claim construction, discovery and dispositive motions.
2023	The district court granted Avadel’s invalidity motion concerning the asserted written-description claims.
May 1, 2023	FDA approved LUMRYZ for adult patients with narcolepsy.
2023	Avadel began commercial preparations and launched LUMRYZ.
2024	The Federal Circuit affirmed the district court’s invalidity determination.

The litigation moved quickly because the case affected the commercial launch of a product with potential to compete directly against Xyrem and Xywav. Avadel’s approval and launch reduced the practical value of further proceedings concerning an injunction based on the invalid patents.

Why did the court find Jazz’s patents invalid?

The central issue was written description under 35 U.S.C. § 112. A patent specification must demonstrate that the inventor possessed the claimed invention as of the filing date. The specification does not satisfy this requirement merely because a skilled person could later devise or recognize the claimed subject matter.

The district court concluded that the asserted patent claims covered a broader combination of sodium oxybate formulation and dosing characteristics than the patent specification adequately described. The court found that the written description did not provide sufficient support for the full scope of the claims asserted against Avadel.

This distinction mattered because Jazz’s patent claims were not limited to the specific examples disclosed in the specification. The claims reached a broader class of sodium oxybate products and administration conditions. The court determined that the specification did not show possession of that full claim scope.

The invalidity ruling was based on written description rather than a finding that LUMRYZ lacked FDA approval, lacked clinical efficacy or was commercially equivalent to Xyrem. The case was decided on patent-support grounds.

What was the Federal Circuit outcome?

The Federal Circuit affirmed the district court’s determination that the asserted claims were invalid for lack of written description. The appellate decision left the invalidity ruling in place and removed the principal patent obstacle to Avadel’s LUMRYZ launch.

The appellate outcome was significant for three reasons:

1. Jazz could not obtain an injunction based on the asserted patents.
2. Avadel retained the ability to market LUMRYZ without a court-imposed launch restriction based on those claims.
3. Jazz’s broader sodium oxybate patent strategy suffered a direct loss in a case involving the most commercially important competing product.

The decision did not invalidate every Jazz patent relating to sodium oxybate. It addressed the patents and claims at issue in the litigation. Other patents, regulatory exclusivities, trade secrets, risk-management controls and commercial contracting rights required separate analysis.

What was the FDA and Orange Book status?

FDA approved LUMRYZ on May 1, 2023, for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. LUMRYZ is an extended-release oral suspension containing sodium oxybate.

Xyrem is subject to a restricted distribution system and a risk evaluation and mitigation strategy designed to address sodium oxybate’s central nervous system depressant effects, abuse potential and risks when combined with alcohol or sedatives. LUMRYZ operates in the same controlled-substance and narcolepsy treatment market but uses a different dosing architecture.

The case was not a biosimilar dispute. LUMRYZ is a small-molecule sodium oxybate product regulated through the new drug application pathway rather than the Public Health Service Act biosimilar pathway.

Jazz’s Orange Book listings were important because they triggered patent litigation after Avadel’s regulatory filing. The court’s invalidity ruling reduced the enforceability of the asserted Orange Book patents against LUMRYZ. Orange Book listing alone does not establish validity or infringement.

Did Avadel file a Paragraph IV challenge?

Avadel’s regulatory filing and Jazz’s subsequent patent suit placed the dispute within the Hatch-Waxman framework. Avadel’s position was that the asserted patents were invalid, unenforceable or not infringed. A Paragraph IV certification permits an applicant to challenge listed patents by asserting that the patents are invalid, unenforceable or not infringed.

The resulting litigation was not a conventional generic substitution case. Avadel developed LUMRYZ as a differentiated extended-release product rather than as a direct formulation copy of immediate-release Xyrem. That distinction affected both the patent analysis and the commercial launch strategy.

The court’s decision effectively resolved the asserted patent threat in Avadel’s favor. It did not require Avadel to wait for the asserted patents’ nominal expiration dates before commercializing LUMRYZ.

What formulation patents protect Xyrem and LUMRYZ?

Xyrem is an immediate-release sodium oxybate product administered in two doses during the night. LUMRYZ is an extended-release sodium oxybate formulation administered once at bedtime.

The principal technical battleground was whether Jazz’s patent disclosures adequately supported claims broad enough to cover the formulation and dosing characteristics used by LUMRYZ. The litigation demonstrated the difficulty of using later-filed continuation claims to capture a competing controlled-release product when the original specification does not clearly disclose the full breadth of the later claims.

Jazz’s patent estate includes several categories:

• Sodium oxybate composition and formulation patents.
• Dosing and administration method patents.
• Controlled distribution and safety-related intellectual property.
• Continuation and divisional patents directed to specific claim categories.
• Patent rights associated with Xywav and alternative oxybate compositions.

Avadel’s principal technical barrier was the need to develop a once-nightly formulation that maintained therapeutic exposure while controlling sodium load, tolerability and nighttime pharmacokinetics. The litigation did not eliminate those technical barriers. It eliminated two specific patent claims as a legal barrier.

How strong was Jazz’s patent estate after the Avadel decision?

Jazz’s estate was commercially important but materially weakened by the invalidity ruling against the two patents asserted in the Avadel case.

Risk category	Assessment after the decision
Core Xyrem formulation protection	Reduced as older patents approached expiration
Once-nightly competing sodium oxybate products	Weakened by invalidity ruling
Xywav-specific protection	Potentially separate from the asserted patents
Method-of-use protection	Dependent on claim scope, disclosure and Orange Book listing
Regulatory controls and distribution systems	Remain commercial barriers but are not substitutes for patent exclusivity
Trade-secret protection	Potentially relevant to manufacturing and product quality
Litigation leverage against LUMRYZ	Substantially reduced

The decision also exposed a broader estate-management risk. Patent families directed to mature products often rely on continuation practice to pursue later claim scope. If the specification does not provide adequate support for the later claims, the resulting patents can fail even when the underlying product has substantial commercial value.

What generic launch risks existed for LUMRYZ?

LUMRYZ was not a standard immediate-release generic and did not create an automatic pharmacy substitution event for Xyrem. Its commercial entry risk involved several separate factors.

Patent risk

The asserted Jazz patents no longer blocked launch after the invalidity judgment and appellate affirmance.

Regulatory risk

LUMRYZ required its own FDA approval, labeling, manufacturing controls and risk-management compliance. Approval did not depend solely on proving bioequivalence to Xyrem because the products have different release profiles.

Market-access risk

Sodium oxybate products are subject to restricted distribution, prescriber controls, patient enrollment and pharmacy procedures. These controls can slow prescription conversion even after regulatory approval.

Clinical-positioning risk

LUMRYZ’s once-nightly dosing can provide a convenience advantage over two-dose Xyrem therapy. Commercial uptake still depends on physician adoption, payer coverage, patient tolerability and the product’s sodium content and clinical profile.

Competitive response

Jazz can respond through contracting, payer strategy, patient-support programs and continued promotion of Xywav, which contains lower-sodium oxybate salts and addresses concerns associated with sodium exposure.

How does LUMRYZ compare with Xyrem and Xywav?

Factor	Xyrem	Xywav	LUMRYZ
Sponsor	Jazz	Jazz	Avadel
Active ingredient	Sodium oxybate	Mixed oxybate salts	Sodium oxybate
Dosing	Twice nightly	Twice nightly	Once nightly
Release profile	Immediate release	Immediate release	Extended release
Main commercial proposition	Established efficacy and market access	Lower-sodium alternative	Dosing convenience
Patent dispute in this case	Reference product	Separate product strategy	Accused product
FDA approval	Yes	Yes	May 1, 2023
Biosimilar pathway	No	No	No

LUMRYZ competes with Xyrem on sodium oxybate efficacy and with Xywav on convenience, tolerability and physician preference. It does not provide the lower-sodium profile of Xywav, so the products occupy overlapping but distinct commercial positions.

What revenue exposure did the litigation create for Jazz?

The case affected Jazz’s largest therapeutic franchise. Xyrem and Xywav together generated more than $2 billion in annual net sales around the period of LUMRYZ’s approval, according to Jazz’s annual reporting. The exact exposure depended on the rate at which LUMRYZ converted patients from Xyrem, captured new diagnoses or competed with Xywav.

The financial risk was asymmetric:

• Xyrem faced direct product competition from another sodium oxybate.
• Xywav could face indirect pressure from payer and prescriber negotiations.
• LUMRYZ could expand the once-nightly segment rather than simply take existing Xyrem volume.
• Jazz retained established distribution, prescriber relationships and a broad narcolepsy franchise.
• Avadel gained the ability to commercialize without waiting for the asserted patent terms to expire.

The court decision therefore created a material competitive threat without guaranteeing rapid erosion of Jazz revenue. Market-share transfer depended on access, reimbursement and clinical adoption.

Were there licensing deals or settlement agreements?

The reported litigation outcome was a merits resolution based on invalidity, not a commercial settlement granting Avadel a delayed license to Jazz’s asserted patents. No Jazz-Avadel license was required for LUMRYZ commercialization after the asserted claims were held invalid.

Avadel’s product originated from its development of FT218, an extended-release sodium oxybate program. The relevant commercial rights were associated with Avadel’s own development and acquisition history rather than a license from Jazz covering LUMRYZ.

The absence of a settlement preserved direct competition between the companies. Jazz did not receive a royalty-bearing license arrangement that would offset the competitive effect of LUMRYZ.

What litigation remains relevant after the case?

The decision resolved the asserted patent claims in Civil Action No. 1:21-cv-01594. It did not eliminate every possible dispute involving oxybate products.

Relevant residual issues include:

• Separate Jazz patents not asserted or not adjudicated in this case.
• Patent disputes involving Xywav or later Jazz formulations.
• Future patents covering LUMRYZ manufacturing, dosing or delivery technology.
• Regulatory exclusivity and pediatric exclusivity questions.
• Restricted-distribution and controlled-substance compliance.
• Payer contracting and market-access disputes.
• Potential patent challenges by later sodium oxybate entrants.

The case also has precedent value for continuation patenting. Courts may reject broad continuation claims when the original specification does not demonstrate possession of the claimed formulation or dosing combination.

Key Takeaways

• Jazz sued Avadel in Delaware in 2021 over LUMRYZ, a once-nightly extended-release sodium oxybate product.
• The case involved U.S. Patent Nos. 8,731,963 and 10,758,488.
• The asserted claims were held invalid for lack of written description under 35 U.S.C. § 112.
• The Federal Circuit affirmed the invalidity ruling.
• FDA approved LUMRYZ on May 1, 2023.
• The ruling removed the principal patent barrier to LUMRYZ commercialization.
• LUMRYZ is a differentiated NDA product, not a biosimilar and not a conventional immediate-release generic.
• Jazz retained other commercial, regulatory and intellectual-property defenses, but its patent leverage against once-nightly sodium oxybate competition declined.
• The litigation exposed a written-description weakness in Jazz’s continuation patent strategy.

FAQs About Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals

Did Avadel win the Jazz patent lawsuit?

Yes. Avadel prevailed on the asserted patent claims after the district court held them invalid for lack of written description. The Federal Circuit affirmed the result.

When did LUMRYZ receive FDA approval?

FDA approved LUMRYZ on May 1, 2023, for adults with narcolepsy who experience cataplexy or excessive daytime sleepiness.

Is LUMRYZ a generic version of Xyrem?

No. LUMRYZ is a separately developed extended-release sodium oxybate product with once-nightly dosing. It is not a biosimilar and does not operate through the biologics approval pathway.

Can Jazz still enforce other Xyrem patents against Avadel?

The invalidity ruling applies to the patents and claims adjudicated in the case. It does not automatically invalidate every other Jazz patent covering Xyrem, Xywav or oxybate technology.

What is the main commercial advantage of LUMRYZ?

LUMRYZ is administered once nightly, while Xyrem and Xywav generally require two nighttime doses. The dosing difference is the product’s principal commercial distinction.

References

1. Avadel Pharmaceuticals plc. (2023). Annual report and corporate disclosures concerning LUMRYZ and FT218.
2. Food and Drug Administration. (2023, May 1). FDA approves new once-nightly drug for adults with narcolepsy.
3. Jazz Pharmaceuticals plc. (2023). Annual report for the fiscal year ended December 31, 2023.
4. Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, No. 1:21-cv-01594, U.S. District Court for the District of Delaware.
5. U.S. Court of Appeals for the Federal Circuit. (2024). Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, appellate decision affirming invalidity of the asserted patent claims.
6. U.S. Patent Nos. 8,731,963 and 10,758,488. United States Patent and Trademark Office.